Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children's Hospital: A 12-Month Survey

Title

Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children's Hospital: A 12-Month Survey

Creator

Kanaparthi Anuradha; Kukura Sarah; Slenkovich Natalie; AlGhamdi Faris; Shafy Shabana Z; Hakim Mohammed; Tobias Joseph D

Publisher

Clinical Pharmacology: Advances and Applications

Date

2019
1905-07

Description

Introduction: Aprepitant (Emend®) is a novel antiemetic agent that works through antagonism of neurokinin-1 (NK-1) receptors. To date, there are limited data regarding its use to prevent postoperative nausea and vomiting (PONV) in children. We retrospectively reviewed our initial 12-months experience with aprepitant after it was made available for perioperative use. Methods: The anesthetic records of patients who received aprepitant were retrospectively reviewed and demographic, surgical, and medication data retrieved. Results: The study cohort included 31 patients (15 male and 16 female) ranging in age from 4 to 27 years (15.7 ± 7.4 years) and in weight from 14.4 to 175.7 kilograms (59.3 ± 30.2 kgs). Most of the patients (30 of 31) received the capsule form and 1 received the liquid. The average dose of aprepitant administered was 0.9 ± 0.6 mg/kg; however, only one patient received dosing expressed as mg/kg, and the majority received a 40 mg capsule. All of the patients in the cohort had either a previous history of PONV or risk factors for PONV. PONV occurred in the PACU in 1 patient and during the first 24 postoperative hours in 3 additional patients. No adverse effects related to aprepitant use were noted. Conclusion: Aprepitant was easily added to the preoperative regimen for pediatric patients who may require it. Our approach limited overuse and subsequent cost concerns. Future studies with a comparator group and a greater sample size are needed to demonstrate its efficacy, especially in comparison to time-honored agents such as ondansetron. No adverse effects were noted in our limited study cohort.

Subject

aprepitant; pediatric; postoperative nausea and vomiting

Identifier

PMID: 31819673 PMCID: PMC6885572

Format

Journal Article

Search for Full-text

Users with a NEOMED Library login can search for full-text journal articles at the following url: https://libraryguides.neomed.edu/home

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

155-160

Volume

11

ISSN

1179-1438

NEOMED College

NEOMED College of Medicine

NEOMED Department

NEOMED Student Publications; NEOMED College of Medicine Student Publications

Update Year & Number

January 2020 Update

Citation

Kanaparthi Anuradha; Kukura Sarah; Slenkovich Natalie; AlGhamdi Faris; Shafy Shabana Z; Hakim Mohammed; Tobias Joseph D, “Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children's Hospital: A 12-Month Survey,” NEOMED Bibliography Database, accessed March 29, 2024, https://neomed.omeka.net/items/show/10934.